AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05655715 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: 8 Gray x 3
Study NCT05655715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection [Yervoy]
Description: 1 mg/kg IV Q3W for four doses,
Study NCT05655715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab 3mg/kg IV Q3W for four doses, then then Nivolumab 480mg IV Q4W
Study NCT05655715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: From soft tissue metastases.
Study NCT01662869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
Study NCT01662869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
Study NCT01662869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
Study NCT00907894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDT600 (Telbivudine)
Description: LDT600 (Telbivudine)
Study NCT00843791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: treatment with placebo for 3 months
Study NCT00843791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
Study NCT02433834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI
Description: GP MDI
Study NCT02433834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serevent Diskus 50 μg
Study NCT02433834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02229877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40 mg oral capsules administered twice daily for 8.5 days
Study NCT02229877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
Study NCT02229877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
Study NCT02229877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
Study NCT00796965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7268
Description: Solution/Capsule, Oral, once daily
Study NCT00796965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04186910 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The control group will carry the Fitbit for the entire period of the recovery but will receive no feedback and will not have the app downloaded onto the telephone.
Study NCT04186910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback group
Description: The feedback group will carry the Fitbit for the entire period of the recovery and will receive daily feedback on amount of physical activity carried out and percentage completed of target behavior at the end of the day from an app downloaded on their telephone. The feedback group will also participate in weekly one hour meetings focused on enhancing behavioral strategies to increase self-efficacy and motivation. They will also have their fitbit data analyzed and an agreed upon target of daily activity level increase.
Study NCT02246504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU treatment
Study NCT00910715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: doxycycline 100 mg bid, 10 days
Study NCT00910715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: doxycycline 100 mg bid, 15 days
Study NCT00910715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: control subjects without a history of Lyme borreliosis
Study NCT03909776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
Study NCT03458494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Participants will receive meals traditionally consumed in Mediterranean countries
Study NCT03458494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Description: Participants will receive meals with a low content of total fat.
Study NCT03909776 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
Study NCT03819868 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High cost
Description: Surfaces allocated to this group will be treated with a high-cost sealant (Fluroshield®, Dentsply, São Paulo, Brazil), according to the manufacturer's instructions.
Study NCT03819868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Cost
Description: Surfaces allocated to this group will be treated with a low-cost sealant (Prevent®, FGM Produtos Odontológicos, Santa Catarina, Brazil), according to the manufacturer's instructions.
Study NCT01993407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task Switching Training
Description: Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
Study NCT01993407 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Task
Description: Participants will complete four, one-hour training sessions in which they will perform a single task each session
Study NCT03417674 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
Study NCT01977625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine
Description: The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
Study NCT01977625 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
Study NCT04176354 — intervention group
Intervention type: DRUG
Intervention: Palbociclib + an aromatase inhibitor
Description: Palbociclib + an aromatase inhibitor therapy
Study NCT04176354 — intervention group
Intervention type: DRUG
Intervention: Palbociclib + Letrozole
Description: Palbociclib + Letrozole therapy
Study NCT00384137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppression
Study NCT00451282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stepped preventive care
Description: 2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
Study NCT04176354 — intervention group
Intervention type: DRUG
Intervention: Letrozole
Description: Letrozole monotherapy
Study NCT03785522 — intervention group
Intervention type: DRUG
Intervention: Insulin degludec
Description: Patients will be treated with commercially available Tresiba® in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the study doctor and in accordance with the local label. The study doctor will determine the starting dose of Tresiba® as well as any dose adjustments thereafter.
Study NCT01370629 — intervention group
Intervention type: DRUG
Intervention: Vernakalant
Description: Prescribed at the discretion of the physician in accordance with their usual practice
Study NCT00006014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Study NCT03847532 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Sanger sequencing method
Description: Amplification of the examined fragments of the MutYH gene was conducted using the PCR machine TP4-PCR-01-Tertsik (DNA-Technology, Russia) containing 25 μL of the reaction mixture: 0.1-1.0 μg genomic DNA; 0.25 μM of each original oligoprimer; 200 μM of each nucleosidetriphosphate; 1 U Taq polymerase; PCR buffer (500 mM Tris, 500 mM KCl, pH 8.74); 2.5 μL MgCl2 (25 mM)); deionized water; 20-30 μL of mineral oil. For MutYH gene analysis (Transcript ENST00000257430) Primer3 software (http:// frodo.wi.mit.edu/primer3/input.htm) was selected and 16 primer pairs. The variants of the primary structure in the obtained fragments were revealed using SSCP. DNA fragments containing electrophoretically identified variants were sequenced.
Study NCT03962114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B3
Description: capsules with niagen
Study NCT01487018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Navigation Surgery
Description: To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
Study NCT01487018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Surgery
Description: To compare with the experamental group.
Study NCT02234427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 2-week aspirin therapy (81mg/day)
Study NCT01080911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: spinal morphine 0.05 mg
Study NCT01080911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
Study NCT01861730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Study NCT05564156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention groups
Description: The drugs used by the participants within 24-48 hours after hospitalization were recorded. In the case of new prescribing, the recommendations made by the investigators to the physician are recorded in intervention group. The medication reconciliation report will be evaluated before the discharge of the participants and possible omissions discussed with the physician in charge. A detailed medication review will be accomplished by the investigators during the hospitalization of the participants.
Study NCT02811965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pillow Condition 1
Description: The heel is offloaded by placing the heel on a standard hospital pillow.
Study NCT02811965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pillow Condition 2
Description: The heel is offloaded by placing a standard hospital pillow under the calf suspending the heel above the hospital bed mattress.
Study NCT02180425 — intervention group
Intervention type: DRUG
Intervention: Tretinoin or Adapalene
Description: Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
Study NCT02180425 — intervention group
Intervention type: DRUG
Intervention: Isotretinoin
Description: Subjects will take one pill once daily for 5 months. Subjects will return after 1 month and after 4-5 months of treatment for skin lipid profiling.
Study NCT02811965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heel Foam Pillow
Description: An economy heel offloading device constructed of egg shell foam.
Study NCT02811965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Offloading Device A
Description: Heel offloading device that utilizes open cell foam to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate.
Study NCT01861730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Study NCT04639570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KneuroKnits
Description: The KneuroKnits program will be based upon current knitting education practices and leading practices in facilitation of social participation for individuals with neurodevelopmental disorders, physical disabilities, and acquired brain injuries. The program will consist of 4 weekly sessions in which participants will learn knitting fundamentals and have opportunities to socialize over a shared occupation. The 4 weekly sessions of the KneuroKnits curriculum will include related knitting and social skills themes of the week. Each session will begin with a structured lesson on the knitting topic of the day, and will then continue into knitting practice and social interaction. Participants will be encouraged to practice their new skills (knitting and social) between sessions, and will be allowed to keep all materials that they use or create.
Study NCT02829229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based obesity treatment (PP)
Description: Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials \& 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
Study NCT02504463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan IV
Description: Single IV administration
Study NCT04355416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin Oral gel
Description: application of curcumin oral gel after scaling and root planing
Study NCT04355416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subgingival scaling and root planing
Description: subgingival scaling and root planing without application of curcumin gel
Study NCT04355416 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: subgingival scaling and root planing
Description: subgingival scaling and root planing without application of curcumin gel
Study NCT00456092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Capsules for oral administration
Study NCT02504463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14c]-Samidorphan sublingual
Description: Single sublingual administration containing radiolabel
Study NCT02504463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14c]-Samidorphan oral
Description: Single oral administration containing radiolabel
Study NCT00456092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration
Study NCT05621421 — intervention group
Intervention type: PROCEDURE
Intervention: FFR and IVUS guided PCI
Description: PCI to the long lesion guided with FFR and IVUS
Study NCT03930901 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health education learning package
Description: Health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), \& nail clipper).
Study NCT04243655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA 330-II
Description: One unit for 2-4 hours treatment, for 3 consecutive days
Study NCT02379949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
Study NCT04243655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical treatment (SMT)
Description: SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
Study NCT04243655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment (SMT)
Description: SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
Study NCT03803514 — intervention group
Intervention type: DRUG
Intervention: Recombinant EPO
Description: Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.
Study NCT03278483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid 300 mg Oral Tablet
Description: Isoniazid tablets 300mg daily plus pyridoxine 50mg daily
Study NCT03278483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin 600 mg Oral Tablet
Description: Rifampin capsules 600mg daily
Study NCT03868917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic paravertebral block using pressure measurement technique
Description: The continuous thoracic paravertebral block using ultrasound machine is combined with pressure measurement during needle advancement.
Study NCT00986609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC-1 peptide vaccine
Description: Given subcutaneously
Study NCT00986609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: poly ICLC
Description: Given intramuscularly
Study NCT00986609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1 peptide-poly-ICLC adjuvant vaccine
Description: Receive adjuvant vaccination
Study NCT00986609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00986609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT00986609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT01382680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guidewire
Description: Use of a guidewire at ERCP for cannulating a stenosis of the biliary tract and for applying a therapeutic device (stent, dilation catheter, others)
Study NCT02843529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altoida: neuropsychological, MRI, EEG and CSF biomarkers
Description: Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects.
Study NCT03029559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia
Description: A single session of IH will last for 45 minutes and will consist of alternating phases of hypoxia(FiO2 :9%-11%) and hyperoxia (FiO2 :22%-38%).~Each hypoxic interval will last for 2 minutes whereas the hyperoxic interval lasts for 1 minute each (15, two-minute episodes of hypoxia and 15, one-minute episodes of hyperoxia).